Real-World Treatment Patterns of Sacubitril/Valsartan: A Longitudinal Cohort Study in Germany
Open Access
- 11 April 2019
- journal article
- research article
- Published by Oxford University Press (OUP) in European Journal of Heart Failure
- Vol. 21 (5) , 588-597
Abstract
Aims: To analyse real-world treatment patterns of sacubitril/valsartan (sac/val) using data from a pharmacy database in Germany. Methods and results: A retrospective cohort study of 26 191 adult patients (aged ≥ 18 years) in the IMS® longitudinal prescriptions database in Germany who were dispensed sac/val from January 2016 to June 2017 was conducted. The analysis included sac/val dose titration assessed in the 6 months from first sac/val prescription; prescriptions of concomitant cardiovascular medications in the 6 months pre- and post-index and compliance and persistence during 12 months post-index. Two-thirds of patients were prescribed the lowest sac/val dose of 50 mg twice daily (b.i.d.) at index and up-titration during the first 6 months was attempted in 41% of these patients. Ten percent of patients prescribed 200 mg b.i.d. at index had to be stably down-titrated; among patients prescribed 50 or 100 mg b.i.d. at index that were up-titrated, > 80% remained on the higher dose. Overall, the mean daily diuretic dose decreased by 25% after initiation of sac/val. High compliance and persistence rates were observed across sac/val doses, increasing with higher sac/val dose at index. Prior dose of angiotensin-converting enzyme inhibitor or angiotensin receptor blocker had only minor impact on first sac/val dose, compliance and persistence. Conclusions: Most patients prescribed sac/val are not initiated on the recommended dose nor up-titrated as recommended by the EU Summary of Product Characteristics. Initiation of sac/val was associated with high persistence and compliance and a dose reduction of diuretics. Barriers to up-titration must be explored.Keywords
Funding Information
- Novartis Pharma AG
This publication has 19 references indexed in Scilit:
- 2016 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart FailureEuropean Journal of Heart Failure, 2016
- Initiating Sacubitril/Valsartan (LCZ696) in Heart Failure: Results of TITRATION, a Double-Blind, Randomized Comparison of Two Uptitration RegimensEuropean Journal of Heart Failure, 2016
- Gute Praxis Sekundärdatenanalyse (GPS): Leitlinien und EmpfehlungenDas Gesundheitswesen, 2015
- Angiotensin–Neprilysin Inhibition versus Enalapril in Heart FailureNew England Journal of Medicine, 2014
- Are Hospitalized or Ambulatory Patients with Heart Failure Treated in Accordance with European Society of Cardiology Guidelines? Evidence from 12 440 Patients of the ESC Heart Failure Long-Term RegistryEuropean Journal of Heart Failure, 2013
- Awareness and perception of heart failure among European cardiologists, internists, geriatricians, and primary care physiciansEuropean Heart Journal, 2008
- Medication Compliance and Persistence: Terminology and DefinitionsValue in Health, 2008
- Persistent Use of Evidence-Based Pharmacotherapy in Heart Failure Is Associated With Improved OutcomesCirculation, 2007
- Adherence to chronic cardiovascular therapies: persistence over the years and dose coverageBritish Journal of Clinical Pharmacology, 2006
- Under-utilization of evidence-based drug treatment in patients with heart failure is only partially explained by dissimilarity to patients enrolled in landmark trials: a report from the Euro Heart Survey on Heart FailureEuropean Heart Journal, 2005